Home » Our products
Our products
We commercialise value-added medicines across a range of therapy areas and formulations, as listed below:
| Product name | Summary of Product Characteristics (SmPC) | Patient Information Leaflet (PIL) | Risk Minimisation Materials | |
|---|---|---|---|---|
| Acetylcysteine 200 mg Powder for Oral Solution | SmPC | PIL | ||
| Bisoprolol fumarate 0.5 mg/ml Oral Solution SF/EF | SmPC | PIL | ||
| Brivaracetam 10 mg/ml Oral Solution SF/EF | SmPC | PIL | ||
| Colecalciferol 1000 IU Capsules | SmPC | PIL | ||
| Flecainide Acetate 25 mg/5 ml Oral Solution SF/EF | SmPC | PIL | ||
| Folic Acid 1 mg/ml Oral Solution SF/EF | SmPC | PIL | ||
| Glycopyrronium Bromide 1 mg/5 ml Oral Solution SF/EF | SmPC | PIL | Risk Minimisation Materials | |
| Glycopyrronium Bromide 2 mg/5 ml Oral Solution SF/EF | SmPC | PIL | Risk Minimisation Materials | |
| Hydrocortisone 5 mg/5 ml Oral Solution SF/EF | SmPC | PIL | ||
| Hydrocortisone 10 mg/5 ml Oral Solution SF/EF | SmPC | PIL | ||
| Iloprost 100 mcg/ml Concentrate for Solution for Infusion | SmPC | PIL | ||
| Melatonin 2 mg Hard Capsules | SmPC | PIL | ||
| Melatonin 3 mg Hard Capsules | SmPC | PIL | ||
| Melatonin 5 mg Hard Capsules | SmPC | PIL | ||
| Melatonin 3 mg Film-Coated Tablets | SmPC | PIL | ||
| Melatonin 1 mg/ml Oral Solution SF/EF | SmPC | PIL | ||
| Metformin 500 mg/5 ml Oral Solution SF | SmPC | PIL | ||
| Metformin 850 mg/5 ml Oral Solution SF | SmPC | PIL | ||
| Metformin 1000 mg/5 ml Oral Solution SF | SmPC | PIL | ||
| Mexiletine Hydrochloride 50 mg Hard Capsules | SmPC | PIL | Risk Minimisation Materials | |
| Mexiletine Hydrochloride 100 mg Hard Capsules | SmPC | PIL | Risk Minimisation Materials | |
| Mexiletine Hydrochloride 200 mg Hard Capsules | SmPC | PIL | Risk Minimisation Materials | |
| Phenobarbital 50 mg/5 ml Oral Suspension SF/EF | SmPC | PIL | ||
| Sertraline Hydrochloride 50 mg/5 ml Oral Suspension SF/EF | SmPC | PIL |
SF = sugar-free, EF = ethanol-free
Job Number: GB-CPL-0-499Â
November 2026
Adverse events should be reported
Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to Drug Safety at drugsafety@clinigengroup.com
or fax: +44 1932 824284.
Medical information enquiries
Email medinfo@colonis.co.uk or phone +44 1932 555 026